Key clinical point: An oral fixed-dose, triple-antibiotic combination offers a promising new approach to the treatment of Crohn’s disease.

Major finding: Clinical remission was achieved in 36.7% of patients with active Crohn’s disease after 26 weeks on RHB-104, compared with 23% of placebo-treated controls.

Study details: This was a phase 3, randomized, double-blind, international clinical trial including 331 patients with active Crohn’s disease at 92 sites.

Disclosures: The presenter reported serving as a consultant to RedHill Biopharma, the study sponsor.